Ra Capital Management, L.P. Acquires 3,802 Shares of Hemab Therapeutics (NASDAQ:COAG) Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. purchased 3,802 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average price of $24.97 per share, for a total transaction of $94,935.94. Following the acquisition, the insider owned 6,375,972 shares of the company’s stock, valued at $159,208,020.84. This represents a 0.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 20th, Ra Capital Management, L.P. purchased 996 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.94 per share, for a total transaction of $24,840.24.
• On Tuesday, May 12th, Ra Capital Management, L.P. purchased 6,387 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.90 per share, for a total transaction of $159,036.30.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 39,869 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.81 per share, for a total transaction of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. purchased 1,483 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.98 per share, for a total transaction of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. purchased 9,906 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The stock was bought at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.63 per share, with a total value of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $25.89 on Friday. Hemab Therapeutics Holdings, Inc. has a 12 month low of $23.00 and a 12 month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.